Abstract: The invention provides ?-amino esters of a hydroxypropylthiazolidine carboxamide derivative, (2S)-3-([1,1?-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide, as well as salts and crystal polymorph s thereof, that can be used to inhibit prostaglandin F receptor. The invention further encompasses methods of treating disorders such as pre-term labor at the early gestational stage by the administration of these substances to a patient in need of treatment.

Abstract: A method for supporting a configuration of an interface is provided, wherein the configuration environment has an overview region that has several subregions. At least one item of information concerning a part of the configuration is displayed in each subregion. For each subregion, an item of information concerning the part of the configuration associated with the subregion is displayed. In the case of a warning and/or error message, a configuration option is displayed so as to be selectable, via which the warning/error message is resolved. The selection of the displayed configuration option causes a functionality to be started via which the displayed configuration option is made possible. In the case of a change in the status of a subregion, the display of the status and/or warning and/or error message and a configuration option derived therefrom in one subregion or several subregions is automatically updated and adapted to the changed status.

Abstract: The invention provides ?-amino esters of a hydroxypropylthiazolidine carboxamide derivative, (2S)-3-([1,1?-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide, as well as salts and crystal polymorph s thereof, that can be used to inhibit prostaglandin F receptor. The invention further encompasses methods of treating disorders such as pre-term labor at the early gestational stage by the administration of these substances to a patient in need of treatment.

Abstract: Nitro-compounds are hydrogenated with an activated Ni catalyst whose Ni/Al alloy also contained one or more elements from the list of Cu, Ag and Au prior to activation. In combination with the Group IB elements mentioned above, this catalyst can also be doped with other elements via their addition to the Ni/Al alloy prior to activation and/or they can be adsorbed onto the surface of the catalyst either during or after the activation of the alloy. The suitable doping elements for the alloy prior to activation in combination with the group IB elements mentioned above are one or more of the elements from the list of Mg, Ti, Ce, Cr, V, Mo, W, Mn, Re, Fe, Co, Tr, Ru, Rh, Pd, Pt and Bi. The suitable doping elements that may be adsorbed onto the surface of the catalyst that was previously doped in the alloy prior to activation with the group IB elements mentioned above are one or more elements from the list Mg, Ca, Ba, Ti, Ce, V, Cr, Mo, W, Mn, Re, Fe, Ru, Co, Rh, Ir, Pd, Pt, Ni, Cu, Ag, Au and Bi.

Abstract: A power relay for a vehicle, in particular a utility vehicle, is disclosed. The power relay contains a housing formed by a connecting base and a housing pot that is placed on the connecting base. Accordingly, two connecting bolts for establishing contact with an on-load circuit are formed by standard screws.

Abstract: A power relay for a vehicle is disclosed. The power relay has a housing formed by a connector base and a housing can set thereon, two connection bolts being inserted into the connector base for contacting a load circuit. The power relay further has a coil subassembly arranged in the housing and containing a solenoid coil and an armature. The armature is coupled by a force-transmission member to a contact bridge and can shift in the housing, under the effect of a magnetic field generated by the solenoid coil, in such a way that the contact bridge can be reversibly moved between a closing position, in which the contact bridge bridges the connection bolts in an electro conducting manner, and an opening position, in which the contact bridge is not in contact with the connection bolts. The housing can is configured as an injection-molded component made of plastic.

Abstract: A high current switch, in particular for a motor vehicle, having a first bus bar, a second bus bar in addition to a first semi-conductor switch that has a control connection and a first transmission connection as well as a second transmission connection. The first transmission connection is placed in direct contact with the first bus bar and the second transmission connection is placed in direct electric contact with the second bus bar.

Abstract: The invention provides ?-amino esters of a hydroxypropylthiazolidine carboxamide derivative, (2S)-3-([1,1?-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide, as well as salts and crystal polymorphs thereof, that can be used to inhibit prostaglandin F receptor. The invention further encompasses methods of treating disorders such as pre-term labor at the early gestational stage by the administration of these substances to a patient in need of treatment.

Abstract: The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neturodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.

Abstract: The invention relates to compounds of formula (I): wherein X, W, Q, R, R1 and R2 have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.

Abstract: The invention relates to compounds of formula (I) wherein R1, R2, X1, X2, Y, Ra, Rb, Q have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis and also in the treatment of cancer disorders.

Abstract: The invention provides 2-carboxamide piperazine compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for the treatment of mammalian infertility.

Abstract: Nitro-compounds are hydrogenated with an activated Ni catalyst that is doped during and/or after activation with one or more elements from the list of Mg, Ca, Ba, Ti, Zr, Ce, Nb, Cr, Mo, W, Mn, Re, Fe, Co, Ir, Ni, Cu, Ag, Au, Rh, Ru and Bi whereas the Ni/Al alloy may not, but preferentially can contain prior to activation one or more doping elements from the list of Ti, Ce, V, Cr, Mo, W, Mn, Re, Fe, Ru, Co, Rh, Ir, Pd, Pt and Bi. If the Ni/Al alloy contained one or more of the above mentioned suitable alloy doping elements prior to activation, the resulting catalyst can then be doped with one or more of the elements from the list of Mg, Ca, Ba, Ti, Zr, Ce, V, Nb, Cr, Mo, W, Mn, Re, Fe, Ru, Co, Rh, Ir, Ni, Pd, Pt, Cu, Ag, Au and Bi by their adsorption onto the surface of the catalyst.

Abstract: Nitro-compounds are hydrogenated with an activated Ni catalyst that has an average particle size (APS) less than 25 ?m and is doped with one or more elements from the list of Mg, Ce, Ti, V, Nb, Cr, W, Mn, Re, Fe, Ru, Co, Rh, Ir, Pt, Cu, Ag, Au and Bi via its/their addition to the alloy before activation and/or doped with one or more elements from the list of Mg, Ce, Ti, V, Nb, Cr, W, Mn, Re, Fe, Ru, Co, Rh, Ir, Ni, Cu, Ag, Au and Bi by their adsorption onto the surface of the activated catalyst.

Abstract: The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

Abstract: The present disclosure describes methods, systems, and computer program products for analyzing historic changes to business objects. One method includes monitoring at least one business object for a modification made to at least one business object node attribute. In response to a monitored modification associated with a particular business object node attribute, a new historical version of the at least one business object node attribute is prepared, the new historical version of the at least one business object node attribute including the modified business object node attribute value. A previous historical version of the at least one business object node attribute is retrieved and updated in response to the monitored modification. The new historical version of the at least one business object node attribute and the updated previous historical version of the at least one business object node attribute are then stored.

Abstract: The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neturodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.

Abstract: The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.

Abstract: The invention provides novel arylamino N-heteroaryl MEK inhibitors of Formula (I): Such compounds are MEK inhibitors that are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation. Also disclosed is the treatment of a hyperproliferative disease in mammals, and pharmaceutical compositions containing such compounds.

Abstract: The present invention is related to the use of 2,3 substituted pyrazine sulfonamides of formula (I) for the treatment and/or prevention of allergic diseases, inflammatory dermatoses and other diseases with an inflammatory component. Specifically, the present invention is related to the use of 2,3 substituted pyrazine sulfonamides for the modulation, notably the inhibition, of CRTH2 activity.